A 72-year-old man from Bangalore is found to have a PSA of 8.5 ng/mL during a routine health check-up. He is asymptomatic with no lower urinary tract symptoms. Digital rectal examination is normal. He has a history of myocardial infarction 2 years ago and is on dual antiplatelet therapy. His life expectancy is estimated at 7–8 years due to significant cardiac comorbidity. What is the most appropriate next step in management?

Explanation

## Clinical Context Asymptomatic man with mildly elevated PSA (8.5 ng/mL), normal DRE, significant cardiac comorbidity, and limited life expectancy (7–8 years). ## Key Decision Points | Factor | Finding | Implication | |--------|---------|-------------| | **Age** | 72 years | Older | | **PSA** | 8.5 ng/mL | Mildly elevated (threshold ~4.0) | | **DRE** | Normal | No palpable abnormality | | **Life expectancy** | 7–8 years | **Limited** | | **Comorbidity** | Prior MI, on dual antiplatelet therapy | High surgical/intervention risk | | **Symptoms** | Asymptomatic | No clinical urgency | ## Why Watchful Waiting is Appropriate **High-Yield:** Watchful waiting (also called "deferred management") is the standard of care for asymptomatic men with limited life expectancy (<10 years), even if PSA is elevated. The rationale is that prostate cancer is slow-growing in most men, and the harms of investigation and treatment (biopsy complications, incontinence, erectile dysfunction, cardiac stress from anaesthesia) outweigh the benefits in men unlikely to die from prostate cancer. **Key Point:** Life expectancy is the **single most important factor** in deciding whether to investigate and treat prostate cancer. Men with <10 years life expectancy should not undergo biopsy or treatment for asymptomatic, screen-detected elevation in PSA. ## Guideline Recommendations 1. **American Cancer Society & NCCN:** Screening and diagnostic workup for prostate cancer should be offered only to men with ≥10 years life expectancy. 2. **EAU Guidelines:** Watchful waiting is recommended for asymptomatic men with limited life expectancy, regardless of PSA level. 3. **Indian Urology Association:** Similar recommendations—life expectancy >10 years is a prerequisite for prostate cancer investigation. **Clinical Pearl:** "Watchful waiting" differs from "active surveillance": - **Watchful waiting:** Deferred management with clinical observation only; used when life expectancy is limited or patient declines treatment. - **Active surveillance:** Regular PSA, DRE, and repeat biopsy in low-risk disease; used when life expectancy is >10 years and patient wishes to avoid upfront treatment. ## Why Not the Other Options? - **Transrectal biopsy:** Invasive, carries risks (infection, bleeding, sepsis), and results would not change management in a man with 7–8 years life expectancy. Dual antiplatelet therapy increases bleeding risk. - **Repeat PSA at 6 weeks + conditional biopsy:** Unnecessary in a man with limited life expectancy; even if PSA is confirmed elevated, biopsy is not indicated. - **Empiric ADT:** No diagnosis of cancer; ADT has significant side effects (hot flushes, erectile dysfunction, bone loss, metabolic syndrome) and is not justified without histologic proof in an asymptomatic man. **Mnemonic:** **LESS** = **L**ife expectancy, **E**arly detection, **S**creening, **S**taging. If life expectancy is <10 years, do not pursue screening or staging investigations. [cite:Harrison 21e Ch 97; Campbell-Walsh Urology 12e Ch 112]